New Study Supports Previous Findings On Actos Bladder Cancer Link
Bernstein Liebhard LLP reports on a new study that provides further support regarding the Actos bladder cancer link.
New York, NY (PRWEB) July 06, 2012
Bernstein Liebhard LLP, a nationwide law firm representing clients who have been injured by dangerous drugs and defective medical devices, reports on a July 3, 2012 study published in the Canadian Medical Association Journal, which found that patients taking Actos face a 22 percent increased risk of bladder cancer.* In conducting the study, researchers analyzed data from 2.6 million people with type 2 diabetes who were prescribed medications from the class known as thiazolidinediones, which includes Actos. The researchers found:
- 3,643 people were diagnosed with bladder cancer;
- Although one randomized controlled trial found no association between Actos and bladder cancer, the other studies combined found a 15 percent increase in risk of bladder cancer in patients taking Actos;
- Overall, researchers found a 22 percent increased risk of bladder cancer associated with Actos use; and
- None of the studies showed a link between bladder cancer and the use of Avandia, another thiazolidinedione that is also used to treat diabetes.
The study´s senior author, Jeffrey A. Johnson, the Canada Research Chair in Diabetes Health Outcomes at the University Of Alberta School Of Public Health, told Healthday.com that he “suspects the link between Actos and bladder cancer would have to be the result of a direct effect of the medication.” Johnson believes that the increased risk of bladder cancer may come from Actos´ effect on the body´s production of insulin, which can be used by cancer cells to grow.
Actos And Bladder Cancer Link Alarms Doctors And Patients
This latest study confirms earlier concerns about Actos adverse effects. A study published May 31, 2012 in the British Medical Journal found that taking Actos for two years can double the risk of developing bladder cancer.** In May 2011, the U.S. Food and Drug Administration (“FDA”) published a study that concluded that there is a link between Actos and bladder cancer; the FDA added a warning label to alert users about Actos side effects.*** While Actos is still available in the United States, it has been recalled in both Germany and France.
Those who allegedly developed bladder cancer as a result of taking Actos may be able to collect compensation for medical expenses, lost wages, pain and suffering, and more. The lawyers at Bernstein Liebhard LLP are currently evaluating and investigating potential Actos claims. For more information about Actos problems, visit http://www.consumerinjurylawyers.com.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs´ Hot List,” recognizing the top plaintiffs´ firms in the country, for the past nine consecutive years. Only two firms in the country have been selected for the Hot List nine years in a row.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2012 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Amy L. Abate. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebBernstein-Liebhard/actos-bladder-cancer-link/prweb9676634.htm